Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 171

Sort by

Sort Order Select

Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

Mark J. Levis, MD, PhD, Alexander E Perl, MD, Hervé Dombret, MD, Hartmut Döhner, MD, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Jorge E Cortes, MD

Blood (2012) 120 (21): 673.

https://doi.org/10.1182/blood.V120.21.673.673

Published: 2012

Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

Blood (2012) 120 (21): 716.

https://doi.org/10.1182/blood.V120.21.716.716

Published: 2012

Journal Articles

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Peter Dreger, MD, Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Andreas Bühler, MD, Thorsten Zenz, MD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Donald Bunjes, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MD, PhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 966.

https://doi.org/10.1182/blood.V120.21.966.966

Published: 2012

Journal Articles

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Blood (2012) 120 (21): 785.

https://doi.org/10.1182/blood.V120.21.785.785

Published: 2012

Journal Articles

Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)

Susanne Hofmann, Vanessa Schneider, Lars Bullinger, Yoko Ono, Anita Schmitt, Lu Zhang, Marlies Götz, Konstanze Döhner, MD, Ph.D, Joannis Mytilineos, Markus Wiesneth, Hartmut Döhner, MD, Michael Schmitt, Jochen Greiner, MD

Blood (2012) 120 (21): 3592.

https://doi.org/10.1182/blood.V120.21.3592.3592

Published: 2012

Journal Articles

IL4 and CD40L Prevent Apoptosis of Chronic Lymphocytic Leukemia Cells Via Intracellular pSTAT6 and NFkB Signaling and Not Via Receptor Kinetics

Daniel Mertens, PhD, Nupur Bhattacharya, PhD, Sarah Häbe, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 3893.

https://doi.org/10.1182/blood.V120.21.3893.3893

Published: 2012

Journal Articles

TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20 + Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial

Thorsten Zenz, MD, Markus Kreuz, Doris Winter, Hanne Helfrich, Maxi Fuge, Heike Horn, MD, Julia Richter, PhD, Reiner Siebert, Lorenz Truemper, MD, Norbert Schmitz, MD, Markus Loeffler, Wolfram Klapper, Andreas Rosenwald, MD, Hartmut Döhner, MD, Michael Pfreundschuh, MD, German Ott, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 546.

https://doi.org/10.1182/blood.V120.21.546.546

Published: 2012

Journal Articles

Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG)

Stephanie Sasse, MD, Magdalena Alram, Medical Student, Horst Mueller, PhD, Lenka Smardova, MD, Bernd Metzner, Hartmut Döhner, MD, Thomas Fischer, MD, Vladan Vucinic, Norbert Schmitz, MD, Kerstin Schäfer-Eckart, John M. Raemaekers, MD, PhD, Oliver Schmalz, MD, Bastian von Tresckow, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2012) 120 (21): 552.

https://doi.org/10.1182/blood.V120.21.552.552

Published: 2012

Journal Articles

Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen

Kirsten Fischer, MD, Jasmin Bahlo, Anna- Maria Fink, MD, Raymonde Busch, Sebastian Böttcher, MD, Jiri Mayer, MD, Peter Dreger, MD, Christian Maurer, Anja Engelke, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD

Blood (2012) 120 (21): 435.

https://doi.org/10.1182/blood.V120.21.435.435

Published: 2012

Journal Articles

Phase I/II Study of Volasertib (BI 6727), an Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results From the Randomized Phase II Part for Volasertib in Combination with Low-Dose Cytarabine (LDAC) Versus LDAC Monotherapy in Patients with Previously Untreated AML Ineligible for Intensive Treatment

Johan Maertens, MD, PhD, Michael Lübbert, MD, Walter Fiedler, MD, Loic Fouillard, Alf Haaland, MD, Joseph M. Brandwein, MD, Stéphane Lepretre, MD, Oumédaly Reman, MD, Pascal Turlure, MD, Gesine Bug, Carsten Müller-Tidow, Alwin Krämer, MD, Florian Voss, PhD, Tillmann Taube, MD, Holger Fritsch, PhD, Hartmut Döhner, MD

Blood (2012) 120 (21): 411.

https://doi.org/10.1182/blood.V120.21.411.411

Published: 2012

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

Journal Articles

Substantially Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial

Blood (2012) 120 (21): 667.

https://doi.org/10.1182/blood.V120.21.667.667

Published: 2012

Journal Articles

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Mario Cazzola, Konstanze Döhner, MD, Jennifer Edelmann, MD, Andreas Bühler, MD, Sabrina Kless, Daniel Mertens, PhD, Raymonde Busch, Silja Mack, MSc, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 710.

https://doi.org/10.1182/blood.V120.21.710.710

Published: 2012

Journal Articles

Expression of Cereblon ( CRBN ) Is Associated with Disease Stage, Genetic Subgroups and Specific Micro-RNAs in Multiple Myeloma

Florian Kuchenbauer, MD, PhD, Johannes Bloehdorn, MD, Miriam Kull, MD, Peter Liebisch, MD, Veronica Teleanu, MD, Britta Kopp, Stefan Knop, Christian Straka, Hermann Einsele, Hartmut Döhner, MD, Christian Langer

Blood (2012) 120 (21): 1820.

https://doi.org/10.1182/blood.V120.21.1820.1820

Published: 2012

Journal Articles

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Walter Fiedler, MD, Sabine Kayser, Maxim Kebenko, M.D., Jürgen Krauter, MD, PhD, Helmut R. Salih, M.D., Katharina Götze, M.D., Daniela Späth, MSc, Gudrun Göhring, MD, Veronica Teleanu, MD, Konstanze Döhner, MD, Arnold Ganser, Hartmut Döhner, MD, Richard F Schlenk, MD

Blood (2012) 120 (21): 1483.

https://doi.org/10.1182/blood.V120.21.1483.1483

Published: 2012

Journal Articles

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Blood (2012) 120 (21): 412.

https://doi.org/10.1182/blood.V120.21.412.412

Published: 2012

Journal Articles

Telomere Length in Mantle Cell Lymphoma.

Billy Michael Chelliah Jebaraj, M.Sc., Dirk Kienle, MD, German Ott, MD, Andreas Rosenwald, MD, Thomas F.E. Barth, Peter Möller, MD, Thorsten Zenz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 2509.

https://doi.org/10.1182/blood.V120.21.2509.2509

Published: 2012

Journal Articles

AML1-ETO Collaborates with the TALE Homeobox Genes MEIS1 and MEIS2 in Inducing AML.

Naidu M Vegi, PhD, Josef Klappacher, MSc, Franz Oswald, PhD, Rainer Claus, MD, Medhanie M Mulaw, PhD, Verena Thiel, Msc, Vijay P.S Rawat, PhD, Leticia Quintanilla Fend, MD, Christoph Plass, PhD, Konstanze Döhner, MD, Hartmut Döhner, MD, Wolfgang Hiddemann, MD, Michaela Feuring Buske, MD, Christian Buske, MD

Blood (2012) 120 (21): 2387.

https://doi.org/10.1182/blood.V120.21.2387.2387

Published: 2012

Journal Articles

Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.

Johannes Bloehdorn, MD, Martin Sill, PhD, Andreas Bühler, MD, Silja Mack, MSc, Doris Winter, Lars Bullinger, MD, PhD, Arefeh Rouhi, PhD, Florian Kuchenbauer, MD, PhD, Daniel Mertens, PhD, Axel Benner, Dipl.Stat., Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 2874.

https://doi.org/10.1182/blood.V120.21.2874.2874

Published: 2012

Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

Blood (2011) 118 (21): 2854.

https://doi.org/10.1182/blood.V118.21.2854.2854

Published: 2011

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Mutated Nucleophosmin 1 (NPM1) Is an Immunogenic Target and Patients with NPM1 mut Acute Myeloid Leukemia (AML) Showed High Expression of Different Leukemia-Associated Antigens (LAAs)

IL4 and CD40L Prevent Apoptosis of Chronic Lymphocytic Leukemia Cells Via Intracellular pSTAT6 and NFkB Signaling and Not Via Receptor Kinetics

TP53 Mutation Is an Independent Predictor of Poor Survival in Untreated Patients with CD20 + Aggressive B-Cell Lymphoma: Analysis within the Ricover-60 Trial

Prognostic Relevance of Dose-Density of DHAP-Reinduction Therapy in Relapsed HL: An Analysis of the German Hodgkin-Study Group (GHSG)

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Substantially Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Expression of Cereblon ( CRBN ) Is Associated with Disease Stage, Genetic Subgroups and Specific Micro-RNAs in Multiple Myeloma

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov No. NCT01180322)

Telomere Length in Mantle Cell Lymphoma.

AML1-ETO Collaborates with the TALE Homeobox Genes MEIS1 and MEIS2 in Inducing AML.

Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Interim Analysis of a Phase II Study of the GCLLSG and fcgcll/MW

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only